Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 1/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 8/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.63 |
| ▸ | KDM1A | O60341 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | RAD52 | P43351 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MERTK | Q12866 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3119082 | 0.87 | KDR (0.63) | NPY5RABCG2KMT2AMEN1PTGS2 | |
| SCHEMBL8891806 | 0.86 | EGFR (0.64) | NPY5RABCG2KMT2AMEN1KDM1A | |
| SCHEMBL3117695 | 0.85 | ABCG2 (0.71) | ABCG2KMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL3108340 | 0.85 | KMT2A (0.65) | NPY5RABCG2KMT2AMEN1POLB | |
| SCHEMBL30960995 | 0.85 | NPY5R (0.66) | NPY5RABCG2KMT2AMEN1KDM1A | |
| SCHEMBL2257238 | 0.85 | NPY5R (0.66) | NPY5RABCG2KMT2AMEN1KDM1A | |
| SCHEMBL6039347 | 0.84 | EGFR (0.65) | NPY5RABCG2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3108501 | 0.84 | NPY5R (0.72) | NPY5RABCG2KMT2AMEN1PTGS2 | |
| SCHEMBL2590796 | 0.84 | NPY5R (0.97) | NPY5RABCG2KMT2AMEN1PTGS2 | |
| SCHEMBL2231403 | 0.84 | NPY5R (0.68) | NPY5RABCG2KMT2AMEN1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-8936840-B2 | Retardation film, polarizing plate, liquid crystal display device, and compound | Konica Minolta, Inc. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8936840-B2 | Retardation film, polarizing plate, liquid crystal display device, and compound | Konica Minolta, Inc. (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| EP-1833511-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| WO-2006074187-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| WO-1997020822-A1 | QUINAZOLIN-2,4-DIAZIRINES AS NPY RECEPTOR ANTAGONIST | NOVARTIS AG (CH) | 1997-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | NPY5R 4665/4885ABCG2 1381/4885KMT2A 3878/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | NPY5R 4462/4885ABCG2 1441/4885KMT2A 4023/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | NPY5R 4665/4885ABCG2 1381/4885KMT2A 3878/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | NPY5R 4665/4885ABCG2 1381/4885KMT2A 3878/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | NPY5R 4665/4885ABCG2 1381/4885KMT2A 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.